Comparing Atreca (NASDAQ:BCEL) & Blueprint Medicines (NASDAQ:BPMC)

Blueprint Medicines (NASDAQ:BPMC) and Atreca (NASDAQ:BCEL) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitability and earnings.

Volatility and Risk

Blueprint Medicines has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500. Comparatively, Atreca has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500.

Earnings & Valuation

This table compares Blueprint Medicines and Atreca’s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Blueprint Medicines	$249.38 million	26.31	-$506.98 million	($4.81)	-22.28
Atreca	N/A	N/A	-$97.16 million	($2.50)	-0.04

Atreca has lower revenue, but higher earnings than Blueprint Medicines. Blueprint Medicines is trading at a lower price-to-earnings ratio than Atreca, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Blueprint Medicines and Atreca’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Blueprint Medicines	-102.15%	-215.07%	-42.50%
Atreca	N/A	-157.90%	-71.39%

Institutional & Insider Ownership

37.5% of Atreca shares are owned by institutional investors. 3.9% of Blueprint Medicines shares are owned by company insiders. Comparatively, 11.3% of Atreca shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings for Blueprint Medicines and Atreca, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Blueprint Medicines	3	3	8	1	2.47
Atreca	0	4	0	0	2.00

Blueprint Medicines currently has a consensus price target of $94.87, indicating a potential downside of 11.50%. Atreca has a consensus price target of $4.00, indicating a potential upside of 4,334.59%. Given Atreca’s higher possible upside, analysts plainly believe Atreca is more favorable than Blueprint Medicines.

Summary

Atreca beats Blueprint Medicines on 8 of the 13 factors compared between the two stocks.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

About Atreca

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.